All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Cardio-Oncology Investigations Begin to Uncover More Links Between CVD and Breast Cancer

February 26th 2025

For American Heart Month, cardiologist Amy M. Ahnert, MD, and oncologist Kevin T. Nead, MD, MPhil, unpacked the link between CVD and breast cancer.

Ibrutinib/Venetoclax/Obinutuzumab Controls Disease at 5 Years in Newly Diagnosed MCL

February 25th 2025

At 5 years of follow-up, sustained disease control was demonstrated with ibrutinib plus venetoclax and obinutuzumab in patients with newly diagnosed MCL.

Updated Clinical Trial Data Reflect Efforts to Optimize IO Combos in Non-ccRCC and MIBC, Fine-Tune ADT-Based Regimens in Prostate Cancer

February 25th 2025

Pedro Barata, MD, provides insights on key updates in RCC, MIBC, and prostate cancer, as discussed during a State of the Science Summit™.

Data Continue to Reshape Treatment Considerations Across Advanced GI Malignancies

February 25th 2025

Mohammed Najeeb Al Hallak, MD, MS explores treatment considerations in advanced pancreatic, colorectal, and neuroendocrine cancers.

OH2 Demonstrates Tolerability and Combination Activity in Advanced Sarcoma

February 25th 2025

OH2 monotherapy was safe and treatment with the agent led to responses in combination with HX008 in locally advanced or metastatic sarcoma.

Isatuximab Plus VRd Wins Japanese Approval for Newly Diagnosed Myeloma

February 25th 2025

Isatuximab plus VRd has been approved in Japan for transplant-ineligible, newly diagnosed multiple myeloma.

FDA Grants Priority Review to Perioperative Pembrolizumab in Resectable HNSCC

February 25th 2025

The FDA has granted priority review to the sBLA for perioperative pembrolizumab plus adjuvant radiotherapy in resectable locally advanced HNSCC.

MD Anderson Receives Nearly $23 Million in CPRIT Funding for Cancer Research, Faculty Recruitment

February 25th 2025

MD Anderson was awarded nearly $23 million from the CPRIT for cancer research and faculty recruitment.

Durvalumab Plus Chemo May be Promising Neoadjuvant Option in UTUC

February 25th 2025

A phase 3 study will be initiated after completion of the first neoadjuvant phase 2 trial of platinum-based chemotherapy plus immunotherapy in UTUC.

Identifying and Addressing the Overlooked Need of Patient Sexual Health

February 25th 2025

During the whirlwind of emotions and obligations brought on by a cancer diagnosis, the sexual health needs of patients are often overlooked by clinicians.

Radioligand Therapies and Emerging Targets Drive Innovation in Prostate Cancer Management

February 24th 2025

Pedro Barata, MD, discusses the expansion of radioligand therapies and the identification of novel targets beyond PSMA in prostate cancer.

Time-Limited Zanubrutinib/Rituximab Yields Durable Remissions in Treatment-Naive CLL

February 24th 2025

Time-limited zanubrutinib/rituximab was well tolerated and continued to elicit remissions 13 months after treatment discontinuation in treatment-naive CLL.

TAR-200 Is Poised to Become a Targeted, Tolerable Addition to BCG-Unresponsive NMIBC Treatment Arsenal

February 24th 2025

Sia Daneshmand, MD, discusses how TAR-200 addresses an unmet need for patients with BCG-unresponsive, high-risk NMIBC.

Efineptakin Alfa Represents Potentially Effective Option in Kaposi Sarcoma

February 24th 2025

The long-acting IL-7 agent efineptakin alfa was tolerable and led to responses in patients with Kaposi sarcoma, including in HIV-associated disease.

Orca-T Promotes T-Cell Activation in Hematologic Malignancies

February 24th 2025

Cameron S. Bader, PhD, discusses findings from a study evaluating the prevalence of FOXP3 and Helios expression in Orca-T recipients.

AUTX-703 Receives FDA Fast Track Designation in Relapsed/Refractory AML

February 24th 2025

The FDA has granted the novel, oral KAT2A/B degrader AUTX-703 fast track designation for the treatment of patients with relapsed/refractory AML.

FDA Accepts sBLA for Nivolumab/Ipilimumab in Unresectable/Metastatic MSI-H/dMMR CRC

February 24th 2025

The combination of nivolumab and ipilimumab is under priority review for the frontline treatment of patients with unresectable/metastatic MSI-H/dMMR CRC.

Anna Parks Receives American Society of Hematology Junior Faculty Scholar Award

February 24th 2025

Anna Parks, MD, Huntsman Cancer Institute investigator, has been awarded the ASH Junior Faculty Scholar Award.

Building the Next Generation of Oncology PAs

February 24th 2025

Noam E. Shabani, MS, PA-C, director of the Dana-Farber Postgraduate PA Oncology Fellowship highlights the program and its impact on improved access to care for patients.

Darolutamide Provides Clinical Benefits vs Other AR Inhibitors in Black and White Patients With nmCRPC

February 24th 2025

Darolutamide generated lower treatment discontinuation rates and longer MFS vs enzalutamide or apalutamide in both Black and White patients with nmCRPC.